Each step. Every patient. Exactly what you need.
Schedule a meeting with us
The 2025 Annual Meeting is happening soon, and we would love to connect with you while in San Antonio. Visit our booth #1414 to learn how we are bringing together germline and tumor genomic testing products to support you across the breast cancer care continuum.
We look forward to seeing you at our booth to learn more about Myriad Oncology’s comprehensive suite of services.
Date: Wednesday, December 10, 2025
Time: 2:30 PM – 3:30 PM CDT
Location: SABCS 2025 | Henry B. Gonzalez Convention Center | San Antonio, TX
Presenter: Gregory Vidal, MD, PhD, and Sara Mokhtary-Myers, MS, CGC
Seats are limited-- be sure to add this session to your agenda.
* This Exhibitor Product Theater is a promotional activity not approved for continuing education credit. The content of this Exhibitor Product Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium®️ (SABCS)
We're proud to share that 8 abstracts have been accepted
Ancestry-specific prevalence of pathogenic variants among patients with breast cancer who do not meet guidelines for genetic testing
Presenter: Timothy Simmons, MStat
Date: Thursday, December 11, 2025
Time: 12:30-2:00 PM
Background: Patients with breast cancer (BC) who harbor germline pathogenic variants (PVs) in hereditary... Show morePatients with breast cancer (BC) who harbor germline pathogenic variants (PVs) in hereditary cancer genes have improved survival when their surgical and treatment decisions are tailored to their specific genetic alterations. Additionally, the identification of germline PVs is crucial for family members, as it allows for interventions that can decrease cancer-related morbidity and mortality. Commonly utilized guidelines recommend genetic testing only under specific conditions: if cancer is diagnosed at a young age, typically at or before the age of 50; if there is a strong family history (FH) of cancer; or if there are specific tumor characteristics. Several studies have demonstrated that many patients who do not meet these criteria unknowingly carry PVs and may, therefore, be receiving suboptimal care. In the United States, Black and Hispanic women face disproportionately high rates of BC mortality, highlighting the importance of genetic testing in these populations. It is unclear whether guideline-based restrictions differentially impact women of certain ancestral backgrounds. Here, we explore this question by estimating PV prevalence among BC patients of Asian, Black/African, Hispanic, Multiple, and White/non-Hispanic ancestries who do not meet guidelines for genetic testing.Show less
Enhancing breast cancer risk assessment in a community imaging center to identify high-risk patients and guide screening and management
Presenter: Tammy McKamie MSN, RN, ACGN, OCN
Date: Thursday, December 11
Background: To evaluate the effectiveness of using Tyrer-Cuzick version 8 (TCv8, herein referred to as TC)... Show moreTo evaluate the effectiveness of using Tyrer-Cuzick version 8 (TCv8, herein referred to as TC) alone compared to a combined approach of a family history assessment, germline testing, and TC with a breast cancer (BC) multiple ancestry polygenic risk score (MA-PRS), in identifying patients at high risk for breast and other cancers at imaging centers. Here we compared approaches for identifying high-risk patients to improve personalized screening and management.Show less
Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in women of self-reported Black/African ancestry
Background: Polygenic risk scores (PRSs) combine information from single-nucleotide polymorphisms (SNPs)... Show morePolygenic risk scores (PRSs) combine information from single-nucleotide polymorphisms (SNPs) across the genome to explain a substantial portion of genetic breast cancer (BC) susceptibility. In previous studies, a multiple-ancestry PRS (MA-385) based on 56 ancestry-informative and 329 BC-associated SNPs was accurate for diverse populations and ranked among the most significant factors affecting the risk of BC development. However, medical guidelines discourage the routine clinical use of PRS, citing a need for studies to evaluate potential interactions between SNPs and environmental and hormonal risk factors in diverse populations. Here, we investigate interactions of MA-385 and individual BC-associated SNPs with clinical risk factors in the widely used Tyrer-Cuzick (TC) model in a large cohort of self-reported Black/African women.Show less
Tumor genomic profiling results in breast cancer patients: A comprehensive analysis from a laboratory research registry
Presenter: Gregory Vidal MD, PhD
Time: 5:00-6:30 PM
Background: Precision oncology has transformed breast cancer care, with comprehensive genomic profiling... Show morePrecision oncology has transformed breast cancer care, with comprehensive genomic profiling (CGP) playing a key role in identifying somatic alterations and biomarkers that guide personalized treatment. Separately, germline testing helps uncover inherited pathogenic variants relevant to therapy and familial risk. Despite the growing use of CGP and germline testing, real-world data on the distribution and clinical relevance of results across diverse breast cancer populations is limited. To better understand the molecular landscape of breast cancer in a real-world setting, we analyzed CGP results from a clinical laboratory research registry, including somatic variant classifications, biomarker profiles, and germline findings.Show less
Co-occurring pathogenic variants in patients with breast cancer
Presenter: Kallie Woods MS, CGC
Background: Numerous studies have examined germline variant rates in individuals with breast cancer... Show moreNumerous studies have examined germline variant rates in individuals with breast cancer (BC), consistently reporting that about 5-10% carry a germline pathogenic variant (PV). Although multiple PVs in a single patient have been documented, such cases are rare and reported in small cohorts. As a result, the clinical implications of multiple PVs remain poorly understood. To address this gap we analyzed a large dataset of patients with BC who underwent germline genetic testing.Show less
Personalized Whole-Genome–Based ctDNA Dynamics During Neoadjuvant Therapy Across Breast Cancer Subtypes: Early Insights From MONITOR-Breast
Presenter: Julia Foldi, MD, PhD
Background: In patients with breast cancer who receive neoadjuvant treatment, therapy adjustments are... Show moreIn patients with breast cancer who receive neoadjuvant treatment, therapy adjustments are primarily guided by predefined imaging and clinical assessments. Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing offers a real-time approach to evaluate treatment response and inform escalation or de-escalation strategies. Prior studies have generally examined binary MRD status at sparse timepoints, resulting in limited resolution and a lack of quantitative data on treatment response. The MONITOR-Breast study employs an ultrasensitive, whole-genome sequencing (WGS)-based assay with frequent ctDNA sampling across the neoadjuvant period. Here, we report initial results from an exploratory analysis of this multi-center, prospective study, and provide a quantitative, high-resolution dataset on ctDNA dynamics.Show less
Ultra-sensitive Molecular Residual Disease Detection in Breast Cancer Using Whole-Genome Sequencing-Based Personalized ctDNA Panels: Preliminary Results from the MONSTAR-SCREEN-3 Project
Presenter: Yoichi Naito, National Cancer Center Hospital East, Kashiwa, Japan
Background: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for detecting molecular... Show moreCirculating tumor DNA (ctDNA) has emerged as a promising biomarker for detecting molecular residual disease (MRD) and is increasingly integrated into both clinical practice and translational research in breast cancer. However, whole-exome sequencing (WES)-based approaches often lack sufficient sensitivity for MRD detection, particularly in low-shedding tumors such as luminal breast cancer. To address this limitation, the MONSTAR-SCREEN-3 study is evaluating an ultra-sensitive MRD assay based on whole-genome sequencing (WGS).Show less
Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ inflammatory breast cancer
Presenter: Ranjan Upadhyay MD, PhD
Background: Inflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by rapid... Show moreInflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by rapid progression and a high risk of relapse despite curative-intent therapy. Outcomes are particularly poor for patients with residual disease following neoadjuvant treatment. Circulating tumor DNA (ctDNA)-based assays offer a noninvasive means of detecting minimal residual disease (MRD) and may enable real-time, risk-adapted decisions regarding adjuvant therapy. However, feasibility and performance data for personalized ctDNA monitoring in IBC remain limited.Show less
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information